GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, reported financial results for the quarter ended June 30, 2026, and provided a business update emphasizing continued execution toward the planned initiation of its pivotal GEO-MVA immunobridging study. The study, expected to begin in the fourth quarter of 2026, will proceed under an expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA).
During the second quarter, GeoVax advanced clinical operations planning, start-up activities, and manufacturing preparedness. The company utilized previously manufactured and released cGMP clinical trial material and advanced its AGE1 continuous cell-line manufacturing platform to support future commercial-scale MVA vaccine production. Engagement with government, public health, and biodefense stakeholders continued regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
David A. Dodd, Chairman and CEO of GeoVax, stated, "During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study. Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense."
GeoVax also continues advancing Gedeptin, its investigational gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism and immune activation profile may complement PD-1-based therapies, such as Merck's Keytruda, by improving responsiveness in immunologically resistant tumors. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4.4 million for the second quarter of 2026, compared to $5.4 million in the same period of 2025. Research and development expenses decreased to $3.1 million from $4.7 million, primarily due to lower costs associated with discontinued activities under the BARDA contract and reduced spending on GEO-CM04S1 clinical activities. General and administrative expenses decreased to $1.3 million from $1.5 million, reflecting lower investor relations consulting costs and reduced stock-based compensation. Cash and cash equivalents stood at $3.1 million as of June 30, 2026.
In May 2026, the company announced a strategic reprioritization to concentrate resources on its lead programs, GEO-MVA and Gedeptin. As part of this decision, GeoVax elected to discontinue active development of its GEO-CM04S1 COVID-19 vaccine candidate, citing the continued evolution and contraction of the global COVID-19 vaccine market and the company's focus on programs with clearer regulatory pathways and stronger demand visibility.
GeoVax believes GEO-MVA is uniquely positioned to help address the growing need for diversified global MVA vaccine manufacturing capacity. The company is prioritizing resources toward execution of the GEO-MVA pivotal immunobridging clinical program, advancement of scalable continuous cell-line manufacturing capabilities, engagement supporting future government and international procurement opportunities, and advancement of Gedeptin combination immunotherapy strategies.
Additional information is included in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.
